Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) — Shaji Kumar (2017) | RDL Network
Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Shaji Kumar, Norbert Grząśko, Sosana Delimpasi, W Wiktor-Jędrzejczak, Sebastian Grosicki, Marie‐Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A Dimopoulos
Shaji Kumar, Norbert Grząśko, Sosana Delimpasi, W Wiktor-Jędrzejczak, Sebastian Grosicki, Marie‐Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A Dimopoulos
Katja Weisel, Meletios A Dimopoulos, Niels W.C.J. van de Donk, Karthik Ramasamy, Barbara Gamberi, Matthew Streetly, Massimo Offidani, Frank Bridoux, Javier de la Rubia, Elisabeth Kueenburg, Shona Collins, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Pieter Sonneveld
Sosana Delimpasi, Meletios A Dimopoulos, Jan Štraub, Argiris Symeonidis, Luděk Pour, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesús G. Berdeja, Petr Pavlíček, Jeffrey Matous, Paweł Robak, Kaveri Suryanarayan, Alison Miller, Miguel Villarreal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski
Meletios A Dimopoulos, Sebastian Grosicki, W Wiktor-Jędrzejczak, Hareth Nahi, Astrid Gruber, Markus Hansson, Catriona Byrne, Richard Labotka, Zhaoyang Teng, Huyuan Yang, Norbert Grząśko, Shaji Kumar
Discussion(0)
No comments yet. Be the first to comment.